Senti Bio Joins Webull Corporate Connect Service Platform

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][7] - The company is advancing off-the-shelf CAR-NK cell therapy programs for oncology, with its lead candidate SENTI-202 targeting acute myeloid leukemia (AML) [1][7] Clinical Development - SENTI-202 has shown promising initial clinical data, achieving minimal residual disease (MRD)-negative complete remissions in 2 out of 3 patients, with a durability of over 6 months as of March 20, 2025 [7] - Senti Bio's Gene Circuits have demonstrated functionality in T cells and the potential for selective targeting of solid tumors in preclinical studies [7] Communication and Investor Relations - The company has joined the Webull Corporate Connect Service platform to enhance communication with shareholders and investors, providing updates on corporate content such as news and earnings reports [3][4] - CEO Timothy Lu emphasized the importance of maintaining effective communication and increasing market awareness among investors [4] Strategic Partnerships and Future Directions - Senti Bio is actively pursuing partnerships to advance its capabilities in cell and gene therapy modalities beyond oncology [7] - The company aims to generate long-term value for stakeholders while continuing to execute on its clinical development plans [4][7]